GB202018950D0 - Parenteral formulation - Google Patents

Parenteral formulation

Info

Publication number
GB202018950D0
GB202018950D0 GBGB2018950.2A GB202018950A GB202018950D0 GB 202018950 D0 GB202018950 D0 GB 202018950D0 GB 202018950 A GB202018950 A GB 202018950A GB 202018950 D0 GB202018950 D0 GB 202018950D0
Authority
GB
United Kingdom
Prior art keywords
parenteral formulation
parenteral
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2018950.2A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Small Pharma Ltd
Original Assignee
Small Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GBGB2018950.2A priority Critical patent/GB202018950D0/en
Application filed by Small Pharma Ltd filed Critical Small Pharma Ltd
Publication of GB202018950D0 publication Critical patent/GB202018950D0/en
Priority to CA3179161A priority patent/CA3179161C/en
Priority to AU2021204158A priority patent/AU2021204158B2/en
Priority to ES21720509T priority patent/ES2928395T3/en
Priority to MX2022014900A priority patent/MX2022014900A/en
Priority to CN202180046463.XA priority patent/CN116056763B/en
Priority to PCT/EP2021/060750 priority patent/WO2021116503A2/en
Priority to PL21720509.5T priority patent/PL3902541T3/en
Priority to NZ794833A priority patent/NZ794833A/en
Priority to KR1020227045704A priority patent/KR102589605B1/en
Priority to JP2022574099A priority patent/JP7288154B2/en
Priority to IL298541A priority patent/IL298541B1/en
Priority to EP21720509.5A priority patent/EP3902541B1/en
Priority to AU2021284861A priority patent/AU2021284861A1/en
Priority to CN202180046533.1A priority patent/CN115996713A/en
Priority to JP2022574098A priority patent/JP2023527575A/en
Priority to US17/320,155 priority patent/US20210378969A1/en
Priority to CA3118556A priority patent/CA3118556A1/en
Priority to PCT/EP2021/062794 priority patent/WO2021244831A1/en
Priority to IL298542A priority patent/IL298542A/en
Priority to EP21725377.2A priority patent/EP4149460A1/en
Priority to GB2106881.2A priority patent/GB2595776B/en
Priority to US17/458,167 priority patent/US11471417B2/en
Priority to PCT/EP2021/083755 priority patent/WO2022117640A1/en
Priority to EP21816489.5A priority patent/EP4255421A1/en
Priority to US18/252,949 priority patent/US20240016782A1/en
Ceased legal-status Critical Current

Links

GBGB2018950.2A 2020-06-02 2020-12-01 Parenteral formulation Ceased GB202018950D0 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
GBGB2018950.2A GB202018950D0 (en) 2020-12-01 2020-12-01 Parenteral formulation
EP21720509.5A EP3902541B1 (en) 2020-06-02 2021-04-23 Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
MX2022014900A MX2022014900A (en) 2020-06-02 2021-04-23 Deuterated compounds.
AU2021204158A AU2021204158B2 (en) 2020-06-02 2021-04-23 Deuterated compounds
ES21720509T ES2928395T3 (en) 2020-06-02 2021-04-23 Therapeutic compositions comprising deuterated or partially deuterated N,N-dimethyltryptamine compounds
CA3179161A CA3179161C (en) 2020-06-02 2021-04-23 Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
CN202180046463.XA CN116056763B (en) 2020-06-02 2021-04-23 Therapeutic compositions comprising deuterated or partially deuterated N, N-dimethyltryptamine compounds
PCT/EP2021/060750 WO2021116503A2 (en) 2020-06-02 2021-04-23 Deuterated compounds
PL21720509.5T PL3902541T3 (en) 2020-06-02 2021-04-23 Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
NZ794833A NZ794833A (en) 2020-06-02 2021-04-23 Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
KR1020227045704A KR102589605B1 (en) 2020-06-02 2021-04-23 Therapeutic composition comprising a deuterated or partially deuterated N,N-dimethyltryptamine compound
JP2022574099A JP7288154B2 (en) 2020-06-02 2021-04-23 Therapeutic compositions containing deuterated or partially deuterated N,N-dimethyltryptamine compounds
IL298541A IL298541B1 (en) 2020-06-02 2021-04-23 1,1-dideuterio-2-(1h-indol-3-yl)-n,n-bis(trideuteriomethyl)ethanamine and therapeutic composition comprising it
AU2021284861A AU2021284861A1 (en) 2020-06-02 2021-05-13 Therapeutic solid dosage forms
GB2106881.2A GB2595776B (en) 2020-06-02 2021-05-13 Therapeutic solid dosage forms
EP21725377.2A EP4149460A1 (en) 2020-06-02 2021-05-13 Therapeutic solid dosage forms
JP2022574098A JP2023527575A (en) 2020-06-02 2021-05-13 Therapeutic solid formulation
US17/320,155 US20210378969A1 (en) 2020-06-02 2021-05-13 Therapeutic solid dosage forms
CA3118556A CA3118556A1 (en) 2020-06-02 2021-05-13 Therapeutic solid dosage forms
PCT/EP2021/062794 WO2021244831A1 (en) 2020-06-02 2021-05-13 Therapeutic solid dosage forms
IL298542A IL298542A (en) 2020-06-02 2021-05-13 Therapeutic solid dosage forms
CN202180046533.1A CN115996713A (en) 2020-06-02 2021-05-13 Therapeutic solid dosage forms
US17/458,167 US11471417B2 (en) 2020-06-02 2021-08-26 Deuterated N,N-dimethyltryptamine compounds
PCT/EP2021/083755 WO2022117640A1 (en) 2020-12-01 2021-12-01 Inhalable formulations
EP21816489.5A EP4255421A1 (en) 2020-12-01 2021-12-01 Inhalable formulations
US18/252,949 US20240016782A1 (en) 2020-12-01 2021-12-01 Inhalable formulations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2018950.2A GB202018950D0 (en) 2020-12-01 2020-12-01 Parenteral formulation

Publications (1)

Publication Number Publication Date
GB202018950D0 true GB202018950D0 (en) 2021-01-13

Family

ID=74099957

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2018950.2A Ceased GB202018950D0 (en) 2020-06-02 2020-12-01 Parenteral formulation

Country Status (1)

Country Link
GB (1) GB202018950D0 (en)

Similar Documents

Publication Publication Date Title
CA202905S (en) Half-boot
IL279083A (en) Parenteral nutrition formulation
CA196956S (en) Onesie
CA208524S (en) Soundbar
CA199411S (en) Handshower
GB202007546D0 (en) Formulation
IL273469A (en) Parenteral formulation comprising siponimod
CA198107S (en) Protractor-ruler
EP4119807A4 (en) Sliding component
EP4130019A4 (en) Metal-carbohydrate complex
GB202018950D0 (en) Parenteral formulation
CA212416S (en) Aéronef
CA212654S (en) Velomobile
CA207518S (en) Smartglasses
CA207516S (en) Smartglasses
CA207519S (en) Smartglasses
CA207517S (en) Smartglasses
CA206631S (en) Mandoline
ZA202105829B (en) Etelcalcetide formulations for parenteral use
CA204910S (en) Volvelle
CA204810S (en) Playard
CA204263S (en) Brushguard
CA204055S (en) Spiralizer
CA201360S (en) Débardeur
CA200872S (en) Nighstand

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)